ULEI hosted our 2nd Annual Meeting at the Grand Hotel Lund, Sweden, between the 9th and 10th of October 2025.
The meeting was a valuable opportunity for in-person discussions, sharing results, and planning future activities. An important part of the event was the roundtable discussion to assess results, upcoming tasks, risks, and mitigation strategies in R&D work packages.
Additionally, the ULEI team updated on the activities in the Cardiogenomics Portfolio, including the upcoming EIC Portfolio event on March 16-17, 2026, focused on networking and a Tech-to-Market event in Leiden organized by ULEI, and INN-ACTA shared information about the outreach to patient organisations. Importantly, the coordinator presented the management and coordination activities and provided details for the upcoming reporting period and review meeting.
The meeting strengthened our connections and commitment within the consortium to further knowledge and identify new biomarkers and therapeutic targets for atherosclerosis.
Thank you to all partners for dedication and contributions, and a special thanks to the organizer for facilitating the meeting and welcoming us to Lund.
